Disclosures: None. A complete listing of grant support for research conducted by CCG and POG before initiation of the COG grant in 2003 is available online at: http://www.childrensoncologygroup.org/admin/grantinfo.htm.
Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group†
Version of Record online: 19 JUL 2006
Copyright © 2006 Wiley-Liss, Inc.
Pediatric Blood & Cancer
Volume 49, Issue 1, pages 17–22, July 2007
How to Cite
Barnard, D. R., Alonzo, T. A., Gerbing, R. B., Lange, B. and Woods, W. G. (2007), Comparison of childhood myelodysplastic syndrome, AML FAB M6 or M7, CCG 2891: Report from the Children's Oncology Group. Pediatr. Blood Cancer, 49: 17–22. doi: 10.1002/pbc.20951
- Issue online: 22 MAY 2007
- Version of Record online: 19 JUL 2006
- Manuscript Accepted: 31 MAY 2006
- Manuscript Received: 11 JAN 2006
- acute myeloid leukemia;
- myelodysplastic syndrome;
Myelodysplastic syndromes (MDS), acute erythroleukemia (FAB M6), and acute megakaryocytic leukemia (FAB M7) have overlapping features.
Children without Down syndrome or acute promyelocytic leukemia who were newly diagnosed with primary myelodysplastic syndrome or acute myeloid leukemia (AML) M6 or M7 were compared to children with de novo AML M0–M5. All children were entered on the Children's Cancer Group therapeutic research study CCG 2891.
The presentation and outcomes of the 132 children diagnosed with MDS (60 children), AML FAB M6 (19 children), or AML FAB M7 (53 children) were similar. Children with AML FAB M7 were diagnosed at a significantly younger age (P = 0.001). Children with MDS, M6, or M7 had significantly lower white blood cell (WBC) counts (P = 0.001), lower peripheral blast counts (P < 0.001), and an increased frequency of −7/7q- (P = 0.003) at presentation. All three groups had significantly inferior overall survival (OS) (P < 0.001) and event free survival (P < 0.001) compared with the 748 children diagnosed with AML FAB M0–M5 when assessed from entry on study. This poor survival was largely attributable to induction death and failure. However, when assessed from successful completion of induction therapy, the 5-year OS (P = 0.090)(49.1 vs. 56.9%) and disease-free survival (DFS) (P = 0.113)(38.0 vs. 46.3%) therapy were not significantly different from other children with AML.
Childhood AML FAB M6 and AML M7 resemble MDS in presentation, poor induction success rates, and outcomes. Pediatr Blood Cancer 2007;49:17–22. © 2006 Wiley-Liss, Inc.